These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 16513858)

  • 21. Blood levels and DA transporter occupancy of orally administered methylphenidate in juvenile rhesus monkeys measured by high resolution PET.
    Wilcox KM; Zhou Y; Wong DF; Alexander M; Rahmim A; Hilton J; Weed MR
    Synapse; 2008 Dec; 62(12):950-2. PubMed ID: 18798297
    [No Abstract]   [Full Text] [Related]  

  • 22. Low dopamine transporter occupancy by methylphenidate as a possible reason for reduced treatment effectiveness in ADHD patients with cocaine dependence.
    Crunelle CL; van den Brink W; Veltman DJ; van Emmerik-van Oortmerssen K; Dom G; Schoevers RA; Booij J
    Eur Neuropsychopharmacol; 2013 Dec; 23(12):1714-23. PubMed ID: 23731497
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chronic oral methylphenidate treatment reversibly increases striatal dopamine transporter and dopamine type 1 receptor binding in rats.
    Robison LS; Ananth M; Hadjiargyrou M; Komatsu DE; Thanos PK
    J Neural Transm (Vienna); 2017 May; 124(5):655-667. PubMed ID: 28116523
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A positron emission tomography study examining the dopaminergic activity of armodafinil in adults using [¹¹C]altropane and [¹¹C]raclopride.
    Spencer TJ; Madras BK; Bonab AA; Dougherty DD; Clarke A; Mirto T; Martin J; Fischman AJ
    Biol Psychiatry; 2010 Nov; 68(10):964-70. PubMed ID: 21035624
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Measuring dopamine transporter occupancy by cocaine in vivo: radiotracer considerations.
    Fowler JS; Volkow ND; Logan J; Gatley SJ; Pappas N; King P; Ding YS; Wang GJ
    Synapse; 1998 Feb; 28(2):111-6. PubMed ID: 9450511
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Do formulation differences alter abuse liability of methylphenidate? A placebo-controlled, randomized, double-blind, crossover study in recreational drug users.
    Parasrampuria DA; Schoedel KA; Schuller R; Silber SA; Ciccone PE; Gu J; Sellers EM
    J Clin Psychopharmacol; 2007 Oct; 27(5):459-67. PubMed ID: 17873677
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The rate of dasotraline brain entry is slow following intravenous administration.
    Lew R; Constantinescu CC; Holden D; Carson RE; Carroll V; Galluppi G; Koblan KS; Hopkins SC
    Psychopharmacology (Berl); 2020 Nov; 237(11):3435-3446. PubMed ID: 32813030
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults.
    Markowitz JS; Straughn AB; Patrick KS; DeVane CL; Pestreich L; Lee J; Wang Y; Muniz R
    Clin Pharmacokinet; 2003; 42(4):393-401. PubMed ID: 12648029
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vivo quantification of dopamine transporters in mice with unilateral 6-OHDA lesions using [11C]methylphenidate and PET.
    Fischer K; Sossi V; von Ameln-Mayerhofer A; Reischl G; Pichler BJ
    Neuroimage; 2012 Feb; 59(3):2413-22. PubMed ID: 21945469
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stimulant medications: how to minimize their reinforcing effects?
    Volkow ND
    Am J Psychiatry; 2006 Mar; 163(3):359-61. PubMed ID: 16513852
    [No Abstract]   [Full Text] [Related]  

  • 31. Similar bioavailability of dexmethylphenidate extended (bimodal) release, dexmethyl-phenidate immediate release and racemic methylphenidate extended (bimodal) release formulations in man.
    Tuerck D; Wang Y; Maboudian M; Wang Y; Sedek G; Pommier F; Appel-Dingemanse S
    Int J Clin Pharmacol Ther; 2007 Dec; 45(12):662-8. PubMed ID: 18184535
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies.
    Swanson J; Gupta S; Lam A; Shoulson I; Lerner M; Modi N; Lindemulder E; Wigal S
    Arch Gen Psychiatry; 2003 Feb; 60(2):204-11. PubMed ID: 12578439
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers.
    Wang Y; Lee L; Somma R; Thompson G; Bakhtiar R; Lee J; Rekhi GS; Lau H; Sedek G; Hossain M
    Biopharm Drug Dispos; 2004 Mar; 25(2):91-8. PubMed ID: 14872557
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Measurement of psychological state changes at low dopamine transporter occupancy following a clinical dose of mazindol.
    Kimura Y; Maeda J; Yamada M; Takahata K; Yokokawa K; Ikoma Y; Seki C; Ito H; Higuchi M; Suhara T
    Psychopharmacology (Berl); 2017 Feb; 234(3):323-328. PubMed ID: 27766370
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Methylphenidate and cocaine have a similar in vivo potency to block dopamine transporters in the human brain.
    Volkow ND; Wang GJ; Fowler JS; Fischman M; Foltin R; Abumrad NN; Gatley SJ; Logan J; Wong C; Gifford A; Ding YS; Hitzemann R; Pappas N
    Life Sci; 1999; 65(1):PL7-12. PubMed ID: 10403500
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Single- and multiple-dose pharmacokinetics of methylphenidate administered as methylphenidate transdermal system or osmotic-release oral system methylphenidate to children and adolescents with attention deficit hyperactivity disorder.
    Pierce D; Katic A; Buckwalter M; Webster K
    J Clin Psychopharmacol; 2010 Oct; 30(5):554-64. PubMed ID: 20814325
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SEP-225289 serotonin and dopamine transporter occupancy: a PET study.
    DeLorenzo C; Lichenstein S; Schaefer K; Dunn J; Marshall R; Organisak L; Kharidia J; Robertson B; Mann JJ; Parsey RV
    J Nucl Med; 2011 Jul; 52(7):1150-5. PubMed ID: 21680689
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Depressed dopamine activity in caudate and preliminary evidence of limbic involvement in adults with attention-deficit/hyperactivity disorder.
    Volkow ND; Wang GJ; Newcorn J; Telang F; Solanto MV; Fowler JS; Logan J; Ma Y; Schulz K; Pradhan K; Wong C; Swanson JM
    Arch Gen Psychiatry; 2007 Aug; 64(8):932-40. PubMed ID: 17679638
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of methylphenidate after oral administration of immediate and sustained-release preparations in Beagle dogs.
    Lavy E; Prise U; Soldani G; Neri D; Brandriss N; Bar Chaim A; Giorgi M
    Vet J; 2011 Sep; 189(3):336-40. PubMed ID: 20696604
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Blockade of striatal dopamine transporters by intravenous methylphenidate is not sufficient to induce self-reports of "high".
    Volkow ND; Wang GJ; Fowler JS; Gatley SJ; Logan J; Ding YS; Dewey SL; Hitzemann R; Gifford AN; Pappas NR
    J Pharmacol Exp Ther; 1999 Jan; 288(1):14-20. PubMed ID: 9862747
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.